ABCL-503 Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

Autor: Westin, Jason, Hoffmann, Marc S., Vassilakopoulos, Theodoros, Munoz, Javier L., Jurczak, Wojciech, Yeh, Su-Peng, Zimowska-Curyło, Dagmara, Kwiatek, Michał, Martín García-Sancho, Alejandro, Sudhindra, Akshay, Gkasiamis, Argyrios, Patel, Arpankumar, Boucaud, Floriane, Petel, Adrien, Kaplan, Mark, Basavanhally, Tara, Li, Ju, Nowakowski, Grzegorz
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S482-S482
Databáze: ScienceDirect
Externí odkaz: